Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach

<b>Background:</b> Both bromodomain and extra-terminal domain (BET) proteins and spleen tyrosine kinase (SYK) represent promising targets in diffuse large B-cell (DLBCL) and Burkitt’s lymphoma (BL). We evaluated the anti-lymphoma activity of the isoform-specific bivalent BET inhibitor AZ...

Full description

Bibliographic Details
Main Authors: Sina Sender, Ahmad Wael Sultan, Daniel Palmer, Dirk Koczan, Anett Sekora, Julia Beck, Ekkehard Schuetz, Leila Taher, Bertram Brenig, Georg Fuellen, Christian Junghanss, Hugo Murua Escobar
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
BET
I-BET151
AZD5153
entospletinib
SYK
gene expression
Online Access:https://www.mdpi.com/2072-6694/14/19/4691

Internet

https://www.mdpi.com/2072-6694/14/19/4691

Similar Items